10-QPeriod: Q1 FY2001

QUEST DIAGNOSTICS INC Quarterly Report for Q1 Ended Mar 31, 2001

Filed May 3, 2001For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported its first quarter 2001 financial results, showing a significant increase in net income to $35.7 million, more than double the $17.8 million reported in the same period of 2000. This strong performance was driven by a 7% growth in net revenues (excluding prior year's third-party testing revenue impact), attributed to improved pricing, a favorable shift in the test mix towards higher-value services, and a better payer mix. The company continued to realize substantial synergies from the integration of SmithKline Beecham Clinical Laboratories (SBCL), with approximately $25 million in synergies achieved in the quarter, annualized at $100 million. This integration is nearing completion, with over 96% of affected business transitioned by the end of March 2001, and the remainder expected to conclude in the second quarter of 2001. These synergies, combined with a reduction in net interest expense and improved revenue per requisition, were key drivers of the improved profitability. Investments in strategic initiatives like Six Sigma quality, IT, and growth opportunities were noted as offsets to profitability improvements.

Key Highlights

  • 1Net income for the quarter surged to $35.7 million, a 101% increase from $17.8 million in Q1 2000.
  • 2Net revenues grew by 7% year-over-year (excluding the impact of prior-year third-party testing arrangements), driven by improved pricing and test mix.
  • 3The integration of SmithKline Beecham Clinical Laboratories (SBCL) is nearing completion, with significant synergies realized ($25 million in Q1 2001, annualized at $100 million).
  • 4Operating expenses as a percentage of net revenues improved due to synergies, better revenue per requisition, and reduced bad debt expense.
  • 5Selling, general, and administrative expenses decreased to 28.6% of net revenues from 30.3% in the prior year.
  • 6Net interest expense decreased significantly due to lower debt levels and favorable financing arrangements.
  • 7The company acquired the assets of Clinical Laboratories of Colorado, LLC (CLC) for $47 million, strengthening its market presence.
  • 8Quest Diagnostics is planning a two-for-one stock split, subject to stockholder approval.

Frequently Asked Questions

The significant increase in net income was primarily driven by a 7% growth in net revenues, largely due to improved average revenue per requisition, a favorable shift in the test mix towards higher-value services, and a better payer mix. Additionally, substantial cost synergies from the ongoing integration of SmithKline Beecham Clinical Laboratories (SBCL) and a reduction in net interest expense contributed significantly to the improved profitability.

The integration of SBCL is nearing completion, with over 96% of the affected business transitioned by the end of March 2001. The company expects the remaining integration activities to conclude in the second quarter of 2001. This integration has yielded significant cost synergies, with approximately $25 million realized in the first quarter of 2001, which the company projects to annualize at $100 million. Management anticipates realizing $100-$120 million in synergies for the full year 2001.

As of March 31, 2001, Quest Diagnostics had $120.7 million in cash and cash equivalents, a decrease from the prior year end due to investing and financing activities. Net cash from operating activities provided $40.7 million. The company's net interest expense decreased significantly due to a reduction in overall debt levels and the favorable impact of its receivables financing and lower interest rates on variable debt. Management believes its cash from operations, available credit facilities, and indemnifications provide sufficient financial flexibility.

Yes, Quest Diagnostics acquired the assets of Clinical Laboratories of Colorado, LLC (CLC) for $47 million on February 1, 2001, to expand its market presence. Additionally, subsequent to the quarter end, the company signed an agreement to acquire MedPlus, Inc., a developer of clinical connectivity and data management solutions, for an estimated $18 million, expected to close in June 2001.